Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.9295 USD +1.41% Intraday chart for Seres Therapeutics, Inc. +2.13% -33.61%
May. 09 Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating MT
May. 09 Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Seres Therapeutics: Q1 Earnings Snapshot
AQ
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K
PU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
BU
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
BU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
BU
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
BU
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
BU
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SERES THERAPEUTICS ANNOUNCES VOWST COMMERCIAL LAUNCH UPDATE AND US FDA FAST TRACK DESIGNATION FOR SER-155
AQ
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
BU
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BU
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.
  5. Press Releases